[1]
Rampa, A.; Gobbi, S.; Belluti, F.; Bisi, A. Tackling Alzheimer’s disease with existing drugs: playing dirty for bypassing obstacles. Curr. Med. Chem., 2021, 28(12), 2305-2327.
[http://dx.doi.org/10.2174/0929867327666200831140745] [PMID: 32867634]
[http://dx.doi.org/10.2174/0929867327666200831140745] [PMID: 32867634]
[2]
El Massry, M.; Alaeddine, L.M.; Ali, L.; Saad, C.; Eid, A.A. Metformin: a growing journey from glycemic control to the treatment of alzheimer’s disease and depression. Curr. Med. Chem., 2021, 28(12), 2328-2345.
[http://dx.doi.org/10.2174/0929867327666200908114902] [PMID: 32900343]
[http://dx.doi.org/10.2174/0929867327666200908114902] [PMID: 32900343]
[3]
Ren, X.; Xu, W.; Sun, J.; Dong, B.; Awala, H.; Wang, L. Current trends on repurposing and pharmacological enhancement of andrographolide. Curr. Med. Chem., 2021, 28(12), 2346-2368.
[http://dx.doi.org/10.2174/0929867327666200810135604] [PMID: 32778020]
[http://dx.doi.org/10.2174/0929867327666200810135604] [PMID: 32778020]
[4]
Shakkour, Z.; Issa, H.; Ismail, H.; Ashekyan, O.; Habashy, K.J.; Nasrallah, L.; Jourdi, H.; Hamade, E.; Mondello, S.; Sabra, M.; Zibara, K.; Kobeissy, F. Drug repurposing: promises of edaravone target drug in traumatic brain injury. Curr. Med. Chem., 2021, 28(12), 2369-2391.
[http://dx.doi.org/10.2174/0929867327666200812221022] [PMID: 32787753]
[http://dx.doi.org/10.2174/0929867327666200812221022] [PMID: 32787753]
[5]
Anwar, F.; Naqvi, S.; Al-Abbasi, F.A.; Neelofar, N.; Kumar, V.; Sahoo, A.; Kamal, M.A. Targeting COVID-19 in parkinson’s patients: drugs repurposed. Curr. Med. Chem., 2021, 28(12), 2392-2408.
[http://dx.doi.org/10.2174/0929867327666200903115138] [PMID: 32881656]
[http://dx.doi.org/10.2174/0929867327666200903115138] [PMID: 32881656]
[6]
El-Hachem, N.; Fardoun, M.M.; Slika, H.; Baydoun, E.; Eid, A.H. Repurposing cilostazol for Raynaud’s phenomenon. Curr. Med. Chem., 2021, 28(12), 2409-2417.
[http://dx.doi.org/10.2174/0929867327666200903114154] [PMID: 32881655]
[http://dx.doi.org/10.2174/0929867327666200903114154] [PMID: 32881655]
[7]
Poitras, E.L.; Gust, S.L.; Kerr, P.M.; Plane, F. Repurposing of the PDE5 inhibitor sildenafil for the treatment of persistent pulmonary hypertension in neonates. Curr. Med. Chem., 2021, 28(12), 2418-2437.
[http://dx.doi.org/10.2174/0929867327666200923151924] [PMID: 32964819]
[http://dx.doi.org/10.2174/0929867327666200923151924] [PMID: 32964819]
[8]
Sobenin, I.A.; Markin, A.M.; Glanz, V.Y.; Markina, Y.V.; Wu, W-K.; Myasoedova, V.A.; Orekhov, A.N. Prospects for the use of sialidase inhibitors in anti-atherosclerotic therapy. Curr. Med. Chem., 2021, 28(12), 2438-2450.
[http://dx.doi.org/10.2174/0929867327666200831133912] [PMID: 32867633]
[http://dx.doi.org/10.2174/0929867327666200831133912] [PMID: 32867633]
Related Journals
Current Pharmaceutical Design
Current Topics in Medicinal Chemistry
Current Respiratory Medicine Reviews
Infectious Disorders - Drug Targets
Endocrine, Metabolic & Immune Disorders - Drug Targets
Anti-Infective Agents
Coronaviruses
Recent Advances in Inflammation & Allergy Drug Discovery
Current Probiotics
Article Metrics
8
1